We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Green Lights Priority Review of Sanofi’s Combo Diabetes Drug
FDA Green Lights Priority Review of Sanofi’s Combo Diabetes Drug
The FDA has accepted Sanofi’s application for expedited review of its once-daily, fixed-dose combination of insulin glargine and GLP-1 receptor agonist lixisenatide for Type 2 diabetes.